Recent Public Laws
In addition to legislative proposals pending in the current Congress, this page provides summaries of recent cancer-related legislation that has passed in both the House and Senate and has been signed into law by the President.
The public laws highlighted here were selected for inclusion due to ongoing interest among the cancer community.
Henrietta Lacks Enhancing Cancer Research Act of 2019 (Public Law No: 116-291)
- The Henrietta Lacks Enhancing Cancer Research Act of 2019 requires a Government Accountability Office report on steps federal agencies are taking to reduce barriers to access to federally funded cancer clinical trials from individuals from underrepresented populations. The report will also provide recommendations for addressing these barriers.
- The legislation was introduced in the House as H.R. 1966 by the late Rep. Elijah E. Cummings (D-MD), along with Reps. John Sarbanes (D-MD) and Dutch Ruppersberger (D-MD) on 3/28/2019. Senators Chris Van Hollen (D-MD) and Ben Cardin (D-MD) introduced a companion bill, S. 946, in the Senate on the same date.
- The House passed H.R. 1966 on 12/9/2020, and the Senate passed the bill by Unanimous Consent on 12/18/2020. The President signed the bill into law on 1/5/2021.
- Read the full bill text on Congress.gov.
Further Consolidated Appropriations Act, 2020, P.L. 116-94, Sec. 603 Minimum age of sale of tobacco products
- Language raising the federal minimum to purchase tobacco products from 18 to 21 was included in several pieces of legislation introduced in the 116th Congress, including the Tobacco to 21 Act (S.1258, H.R. 2411) and the Tobacco-Free Youth Act (S. 1541). Provisions from the Tobacco-Free Youth Act were included in P.L. 116-94 as Section 603, “Minimum age of sale of tobacco products.”
- The legislation amends Section 906(d) of the Federal Food, Drug, and Cosmetic Act by raising the federal minimum age for sale of tobacco products from 18 to 21 years of age.
- The law applies to sales of all tobacco products including cigarettes, smokeless tobacco, hookah tobacco, cigars, pipe tobacco, and electronic nicotine delivery systems.
- The President signed the bill on 12/20/19 and the law raising the minimum age to 21 became effective immediately.
- Read the full bill text on Congress.gov (Sec. 603)
Childhood Cancer STAR (Survivorship, Treatment, Access, Research) Act (Public Law No: 115-180)
- This law authorizes NCI to support and expand collection of biospecimens from children, as well as adolescents and young adults (AYAs), diagnosed with cancer to build upon biorepositories and biospecimen research already underway with NCI support. The bill encourages that these efforts focus on cancer types/subtypes (and their recurrences) for which current treatments are least effective, and occur within the context of clinical trials.
- The law also authorizes NIH, with guidance from the NCI Director and in coordination with ongoing research activities, to continue to conduct and support pediatric cancer survivorship research, and includes an emphasis on studying late effects of pediatric cancer treatment, as well as disparities in outcomes and barriers to follow-up care.
- Other provisions specific to NIH and NCI include requiring that at least one member of the presidentially appointed National Cancer Advisory Board be knowledgeable in pediatric oncology; reaffirming reporting requirements for NIH in addressing pediatric oncology research within congressional reporting, including its annual Pediatric Research Initiative Report to Congress; and expressing the sense of Congress that the NCI Director should ensure that all applicable study sections, committees, advisory groups, and panels at NCI should include one or more qualified pediatric oncologists, as appropriate.
- The law also authorizes HHS, through the Centers of Disease Control and Prevention, to award grants to state cancer registries to expand surveillance infrastructure to track the epidemiology of cancer in children and AYAs.
- Additional provisions in the law focused on pediatric cancer survivorship encourage the HHS Secretary to establish pilot programs to evaluate model systems for monitoring and caring for pediatric cancer survivors, and to conduct efforts identify best practices pediatric cancer survivorship care. The law also directs HHS to conduct a review of activities related to workforce development for health care providers who treat pediatric cancer patients and survivors.
- The President signed the bill into law on June 5, 2018.
- Read the full bill text on Congress.gov.
NCI is currently supporting implementation of several Childhood Cancer STAR Act provisions that are directed toward the Institute. As encouraged in Section 202 of the STAR Act, in addition to continuing to conduct and support childhood, adolescent, and young adult (AYA) cancer survivorship research, NCI is also expanding support in this area for new research projects, as described in more detail below.
NCI is also working to enhance biospecimen collection, biobanking, and related resources for childhood and AYA cancers, with an emphasis on those cancer types and subtypes for which treatments are least effective, as specifically encouraged in Section 101 of the STAR Act. NCI convened a meeting on May 13, 2019 with more than 50 representatives from across the childhood cancer research and advocacy communities, focused on challenges and opportunities in this field. More information about the meeting proceedings, including presentations and discussion, is available here in the "Enhancing Biobanking for Childhood Cancers Meeting Minutes". The Institute has identified several additional efforts to enhance biospecimen collection and biobanking across its childhood cancer research programs, as described in more detail below.
Recently funded research efforts and next steps include the following:
- New biospecimen research projects: NCI is supporting several new projects in FY2020 through the Children’s Oncology Group (COG) to focus attention to rare cancer subtypes that are currently underrepresented in NCI-supported biorepositories, as well as tumor types with a high risk of treatment failure. This includes projects with an emphasis on specimens taken at the time of relapse, as well as collecting diagnostic samples for children and AYAs who have already submitted samples at relapse through NCI’s Pediatric MATCH Trial. Projects also include specimen collection within the Childhood Cancer Survivor Study (CCSS) focused on subsequent cancers and chronic health conditions. Project descriptions are as follows:
Children’s Oncology Group (COG) – Rare Tumor Populations Biobanking: For rare cancers for which COG does not have open clinical trials, tumor tissue collection options are limited. This project will support tumor tissue and blood collection for specific groups of patients for which current tumor tissue collection is lacking or inadequate, with priority for tumor types with high risk of treatment failure.
COG – Tumor Specimens from Patients at Relapse: An important impediment to understanding mechanisms of treatment failure for childhood solid tumors is the limited numbers of paired specimens from both diagnosis and relapse that are available for researchers to study. Specimens at relapse are critical for evaluating biological changes between diagnosis and relapse that can lead to the identification of mechanisms of treatment failure and to the development of strategies for circumventing these mechanisms. One area of focus will be collection of relapse specimens from children with rhabdomyosarcoma.
COG – Rapid Autopsy Specimen Collection: NCI and COG plan to work with patient organizations to support rapid autopsy collection of tumor samples from children and AYAs who have died of their disease. Foundations and families within the pediatric brain tumor community have been leaders in such programs, and we hope to learn from their experiences to expand this model to other childhood cancers. We are incredibly grateful to these parents and caregivers, who amidst unimaginable grief and loss, contribute to future research to help other families.
COG – Pediatric MATCH Diagnostic Specimen Collection: This effort to collect diagnostic samples for children and AYAs who have already submitted samples at relapse through NCI’s Pediatric MATCH Trial will enable more in-depth study of the molecular changes that occur between diagnosis and relapse.
CCSS Biobanking I – Specimen Collection of Subsequent Cancers: The development of subsequent malignant neoplasms (SMN) is associated with significant morbidity and mortality for survivors of childhood cancer. The CCSS has prioritized collection of SMN somatic tissue specimens (tissue blocks, scrolls, slides) from survivors with confirmed cases of subsequent malignancies.
CCSS Biobanking II – Specimen Collection to Study Chronic Health Conditions: This project will enhance the CCSS as a resource for future biologic and genetic evaluations to better understand the causes of chronic health conditions in survivors of childhood cancer.
- Additional biospecimen research and biobanking efforts: NCI is also identifying research opportunities that span goals of both the STAR Act and the Childhood Cancer Data Initiative (CCDI). For example, CCDI will support sequencing for specimens collected through the STAR Act projects described above focused on subsequent cancers and on diagnostic specimens collected through the Pediatric MATCH trial. NCI is also initiating a new 5-year grant to support the COG Biorepository. These efforts are being funded in addition to NCI’s investment in STAR Act specific projects.
- New survivorship research projects: NCI issued a new request for applications in January 2019, titled “Improving Outcomes for Pediatric, Adolescent and Young Adult Cancer Survivors”, which directly aligns with survivorship research areas emphasized in the STAR Act. Three new projects were funded under this request for applications (RFA) in FY 2019, and an additional four projects were funded in FY2020. Project descriptions for both FY2020 and FY2019 awards are provided in the table below.
STAR Act Research Projects: Improving Outcomes for Pediatric, Adolescent and Young Adult Cancer Survivors
Project Title, Principal Investigator, Institution, First Fiscal Year of Award
|Tumor Types||Late/Long Term Effect(s)|
Using Information Technology to Improve Outcomes for Children Living with Cancer
PI: Dr. Jin-Shei Lai (Northwestern University at Chicago), FY2019
Disease and treatment-related symptoms
A Randomized Trial of a Mobile Health and Social Media Physical Activity Intervention Among AYA Childhood Cancer Survivors
PI: Dr. Nina Kadan-Lottick (Yale University), FY2019
Utility Of Memantine In Preventing Cognitive Dysfunction In Children Receiving Cranial Radiotherapy
PI: Dr. Nadia Laack (Mayo Clinic), FY2019
|Primary brain tumors||
Cognitive dysfunction after cranial radiotherapy
A web-based patient-reported symptom monitoring and self-management portal for AYA breast cancer survivors
PI: Dr. Ann Partridge (Dana-Farber), FY2020
Symptoms, unmet needs, concerns
Telehealth based exercise intervention to improve functional capacity in survivors of childhood cancer with significantly limited exercise tolerance
PI: Dr. Kirsten Ness (St. Jude), FY2020
Reduced exercise capacity, impaired physical function
An INteractive Survivorship Program to Improve Healthcare REsources [INSPIRE] for Adolescent and Young Adult (AYA) Cancer Survivors
PI: Dr. Karen Syrjala (Fred Hutchinson), FY2020
Emotional distress; adherence
Implementation of a Provider-Focused Intervention for Maximizing HPV Vaccine Uptake in Young Cancer Survivors receiving Follow-Up Care in Pediatric Oncology Practices: A Cluster-Randomized Trial
PI: Dr. Wendy Landier (University of Alabama), FY2020
Elevated risk of HPV-related complications & malignancies
- Collaboration with the Agency for Healthcare Research and Quality (AHRQ): NCI entered into an Inter-Agency Agreement with AHRQ to support its work to implement Section 203 of the STAR Act, focused on identifying best practices in survivorship care, through AHRQ Evidence Reviews on Childhood Cancer Survivorship.
- Ongoing survivorship research efforts: NCI continues its longstanding investment in the Childhood Cancer Survivor Study, which NCI’s Board of Scientific Advisors approved in June 2020 for another 5-year funding period (FY2023-27). The Institute also continues to support a diverse portfolio of survivorship research through investigator-initiated research projects and NCI’s intramural research program.
- New survivorship research funding opportunity: To build upon these research efforts, NCI developed a new funding opportunity posted in April 2020, “Research to Reduce Morbidity and Improve Care for Pediatric, and Adolescent and Young Adult (AYA) Cancer Survivors” (R01: RFA-CA-20-027; R21: RFA-CA-20-028), which also aligns with survivorship research priorities emphasized in the STAR Act. Following peer review, NCI anticipates funding a first round of awards in the summer of 2021, and a second round in the spring of 2022.
Additionally, NCI advisory boards, groups, and committees continue to include pediatric oncologists, scientists with pediatric expertise, and patient advocates, as encouraged in Sections 111 and 112 of the STAR Act. For example:
- National Cancer Advisory Board: Dr. Peter Adamson, Sanofi; Dr. Andrea Hayes-Jordan, University of North Carolina Children’s Hospital
- Board of Scientific Advisors: Dr. Kevin Shannon, University of California San Francisco; Dr. Leslie Robison, St. Jude Children's Research Hospital; Dr. Martine Roussel, St. Jude Children's Research Hospital
- Clinical and Translational Research Advisory Committee: Dr. Anne-Marie Langevin, University of Texas Health Science Center at San Antonio; Dr. Augusto Ochoa, Louisiana State University Health Sciences Center
- Board of Scientific Counselors: Dr. Paul Spearman, Cincinnati Children’s Hospital Medical Center
- National Council of Research Advocates: Danielle Leach, National Brain Tumor Society
- Frederick National Laboratory Advisory Committee: Dr. Catherine Bollard, Children’s National Health System; Dr. Nilsa Ramirez Milan, Nationwide Children's Hospital; Dr. Cheryl Willman, Director, University of New Mexico Comprehensive Cancer Center
- National Clinical Trials Network Steering Committees: More than 40 subject matter experts with pediatric expertise serve across three relevant steering committees (Pediatric and Adolescent Solid Tumors, Brain Malignancies, Pediatric Leukemia and Lymphoma), including a patient advocate serving on each committee.
NCI will also continue to report on childhood cancer research efforts, as directed in Section 121 of the STAR Act, including through the annual NIH Pediatric Research Initiative Report to Congress, as well as the NIH Triennial Report. NCI also reports on activities across its childhood and AYA cancer research portfolio on its website through several pages focused on childhood cancer research and resources for patients and families, and through the Cancer Currents Blog.
FDA Reauthorization Act of 2017 (Public Law No: 115-52)
The FDA Reauthorization Act of 2017 (FDARA) amends the Federal Food, Drug, and Cosmetic Act to revise and extend the user-fee programs for prescription drugs, medical devices, generic drugs, and biosimilar biological products. H.R. 2430 was introduced by Rep. Greg Walden (R-OR) on 5/16/2017 and was signed into law on 8/18/2017, becoming Public Law No: 115-52. The Act includes several provisions relevant to NCI as described below:
The Research to Accelerate Cures and Equity (RACE) for Children Act
The RACE for Children Act was introduced as stand-alone legislation in both the House and Senate earlier this year, and key provisions of the bill were included in FDARA as Section 504, Development of drugs and biological products for pediatric cancers. These provisions amend current study requirements under the Pediatric Research Equity Act (PREA) so that requirements for pediatric studies are based on relevant molecular targets rather than the current requirements, based on cancer site of origin. Additionally, the provisions amend PREA by ending the exemption of PREA obligations for cancer drugs with orphan designations if the molecular target of their drug is relevant to a pediatric cancer.
The Act includes two provisions specifically relevant to NCI, and NCI is currently coordinating with the FDA to begin planning and implementation of these efforts:
- The Act directs the HHS Secretary to consult with both FDA and NCI to develop a list of relevant molecular targets. The Act describes this as "a list of molecular targets considered, on the basis of data the Secretary determines to be adequate, to be substantially relevant to the growth and progression of a pediatric cancer, and that may trigger the requirements under this section."
- The Act directs the HHS Secretary to consult with FDA and NCI and in convening a public meeting within one year after the Act is signed into law to solicit feedback from physicians, researchers, patients, and other stakeholders regarding various aspects of implementation, including development of the list of relevant molecular targets.
NCI continues to collaborate with FDA on implementation of the provisions described above. FDA, in consultation with NCI, hosted a public meeting, as required under the law, on April 20 to review the molecular target list and the Pediatric Subcommittee of the FDA Oncologic Drugs Advisory Committee reviewed and provided comment on the list at their June 18-19, 2018 meeting. In accordance with the statute, the FDA posted the pediatric molecular target list on its website in August 2018. Additional information, including links to the full pediatric molecular target list, is available here on the FDA website.
Enhanced Clinical Trial Design Act of 2017
The Enhanced Clinical Trial Design Act of 2017 was also introduced as stand-alone legislation in the Senate. The bill aims to expand patient access to experimental treatments in clinical trials, including by providing updated guidance on eligibility criteria. Several aspects of this bill are relevant to NCI and were included in the FDA Reauthorization Act of 2017 as well.
- The Act requires the FDA and the NIH to convene a public meeting to discuss clinical trial criteria, including: barriers to participation, alternative clinical trial designs, and potential impact of changes to clinical trial inclusion and exclusion criteria.
- The Secretary is required to issue a public report on the topics discussed at the meeting as well as guidance documents regarding eligibility criteria for clinical trials.
- In addition, the Secretary is required to issue guidance to streamline the institutional review board (IRB) review process for individual pediatric and adult patient expanded access protocol and how the IRBs may facilitate the use of the protocols
Additional Background and Implementation:
Implementation of the provisions described above are underway, and FDA is supporting a public meeting on 4/16/18 to bring the stakeholder community together to discuss a variety of topics related to eligibility criteria in clinical trials, their potential impact on patient access to investigational drugs, and how they might facilitate the enrollment of a diverse patient population. The Enhanced Clinical Trial Design Act of 2017 was originally introduced as S. 1048 by Sens. Orrin Hatch (R-UT), Michael Bennet (D-CO), Richard Burr (R-NC), and Bob Casey (D-PA) on 5/4/2017.
21st Century Cures Act, P.L. 114-255 (H.R. 6/H.R. 34)
- On December 13, 2016, President Obama signed the 21st Century Cures Act (“Cures”) into law. The nearly 1,000-page bill passed the House 392-26 and the Senate by a vote of 94-5. Key provisions for NIH aim to coordinate policies relating to early career investigators, improve loan repayment programs, and streamline procedural requirements for attendance at scientific meetings. Cures reauthorizes the NIH for FY2018-FY2020 at the following levels:
- $34,851,000,000 for FY 2018
- $35,585,871,000 for FY 2019
- $36,472,442,775 for FY 2020
- $34,851,000,000 for FY 2018
- In addition, Cures creates a $4.8 billion "NIH Innovation Account." The funds in the Innovation Account support these specific projects:
- Precision Medicine Initiative -- $1.45 billion over the next 10 years
- Beau Biden Cancer Moonshot -- $1.8 billion over the next seven years
- BRAIN Initiative -- $1.511 million over the next 10 years
- Regenerative Medicines -- $30 million over the next four years
- Beau Biden Cancer Moonshot: One of the key features of the NIH Innovation Account is the Beau Biden Cancer Moonshot. This provision of the law was renamed via a joint amendment introduced by Senate Majority Leader Mitch McConnell (R-KY) and Senate Minority Leader Harry Reid (D-NV), in honor of Vice President Joe Biden's son Beau, who passed away from cancer in 2015. The $1.8 billion for the Cancer Moonshot was authorized to be appropriated as follows:
- $300 million for FY 2017
- $300 million for FY 2018
- $400 million for FY 2019
- $195 million for FY 2020
- $195 million for FY 2021
- $194 million for FY 2022
- $216 million for FY 2023
- Per the Cures statute, the purpose of the Cancer Moonshot funding is: To support cancer research, such as the development of cancer vaccines, the development of more sensitive diagnostic tests for cancer, immunotherapy and the development of combination therapies, and research that has the potential to transform the scientific field, that has inherently higher risk, and that seeks to address major challenges related to cancer.
- Read the full bill text on Congress.gov.
Breast Cancer Commemorative Coin Act, P.L. 114-148 (H.R. 2722/S.2185)
- The bill aims to establish a Breast Cancer Awareness Commemorative Coin by requiring the Secretary of the Treasury to mint up to 50,000 $5 gold coins (to be sold for $35 per coin), up to 400,000 $1 silver coins (to be sold for $10 per coin), and up to 750,000 half-dollar coins (to be sold for $5 per coin) in 2018. Once the cost of design and issuance of the coins is covered, the surcharge would be paid to the Breast Cancer Research Foundation to further research funded by the organization.
- Rep. Carolyn Mahoney (D-NY) introduced H.R. 2722 on 6/10/2015. The bill was referred to the Committees on Financial Services; and the Budget. S.2722 was introduced by Sen. Heidi Heitkamp (D-ND) and referred to the Committee on Banking, Housing, and Urban Affairs on 10/20/15.
- The House passed H.R. 2722 on 7/15/2015 after it was amended to remove Susan G. Komen as a co-recipient after a number of Republican Members of the House objected to the organization’s support for breast cancer screening services provided by Planned Parenthood. The Senate passed the bill on 4/19/2016. The President signed the bill into law (P.L. 114-148) on 4/29/2016.
- Read the full bill text on Congress.gov.
Child Nicotine Poisoning Prevention Act of 2015, P.L. 114-116 (S.142/H.R. 1375/H.R.3243)
- The bill would require the Consumer Product Safety Commission to promulgate a rule to require child safety packaging for liquid nicotine containers.
- The law shall not be construed to limit or otherwise affect the authority of the Secretary of Health and Human Services to regulate, issue guidance, or take action regarding the manufacture, marketing, sale, distribution, importation, or packaging, including child-resistant packaging, of nicotine, liquid nicotine, liquid nicotine containers, electronic cigarettes, electronic nicotine delivery systems or other similar products.
- Sen. Bill Nelson (D-FL) introduced S. 142 on 1/8/2015 and the bill was referred to the Committee on Commerce, Science, and Transportation. Rep. Elizabeth Esty (D-CT) introduced H.R. 1375 on 3/16/15 and the bill was referred to Rep. Susan Brooks (R-IN) introduced H.R. 3243 on 7/28/2015 and the bill was referred to the Committee on Energy and Commerce.
- The Senate passed S. 142 on 12/10/2015, and the House passed the bill on 1/11/2016. The President signed the bill into law (P.L. 114-116) on 1/28/2016.
- Read the full bill text on Congress.gov
Breast Cancer Research Stamp Reauthorization Act of 2015, P.L. 114-99 (S.1170/H.R. 2191)
- The bill would extend the authority of the U.S. Postal Service to issue a semipostal to raise funds for breast cancer research through 2019. Seventy percent of the net proceeds from the Breast Cancer Research Stamp surcharge go to the National Institutes of Health for breast cancer research and 30 percent to the Department of Defense for the same purpose.
- Rep. Jackie Speier (D-CA) introduced H.R. 2191 on 4/30/2015. The bill was referred to the Committees on Armed Services; Energy and Commerce; and Oversight and Government Reform. Sen. Dianne Feinstein (D-CA) introduced S. 1170 on 4/30/2015. The bill was referred to the Committee on Homeland Security and Governmental Affairs.
- The Senate passed S. 1170 by Unanimous Consent on 9/22/2015 and the House passed it on 12/1/2015. The President signed the bill into law (P.L. 114-99) on 12/11/15.
- Read the full bill text on Congress.gov
- Language reauthorizing the Breast Cancer Research Stamp through 2027 was included in the National Defense Authorization Act for Fiscal Year 2020 (P.L. 116-92), which was signed into law on 12/20/19.
Early Act Reauthorization of 2014, P.L. 113-265 (H.R. 5185/S. 2655; 113th Congress)
- The bill aims to reauthorize the Young Women’s Breast Health Education and Awareness Requires Learning Young (EARLY) Act of 2009 for a period of 5 years. The EARLY Act was originally signed into law as section 10413 of the Patient Protection and Affordable Care Act (Public Law 111-148) on 3/23/10.
- Consistent with the original law, the reauthorization proposes to increase awareness of breast cancer risks in young women (15 – 39 years old) and to provide support for those diagnosed with breast cancer.
- The reauthorization would direct CDC to continue implementation of the EARLY Act provisions signed into law in 2010 and does not include new provisions. The bill would direct the CDC to continue to conduct a national evidence-based education campaign to increase public awareness regarding breast cancer in young women, especially regarding risks faced by ethnic and cultural groups. Additionally, the bill would direct the CDC, in consultation with HRSA, to continue an education campaign to increase awareness among physicians and other health care professionals of risk factors, risk reduction strategies, early diagnosis and treatment of breast cancer in young women.
- The bill would also direct the CDC to continue to conduct prevention research on breast cancer in younger women; continue to support research aimed at measuring their awareness of the disease; and continue the activities of its Advisory Committee on Breast Cancer in Young Women.
- The bill would authorize $9 M for each fiscal year from 2015 through 2019. Reps. Debbie Wasserman Schultz (D-FL) and Renee Ellmers (R-NC) introduced H.R. 5185 on 7/24/2014, and Sens. Amy Klobuchar (D-MN) and David Vitter (R-LA) introduced S. 2655 on 7/24/14. H.R. 5185 was referred to the Committee on Energy and Commerce, and S.2655 was referred to the Committee on Health, Education, Labor, and Pensions. The House passed H.R. 5185 on 12/9/14 by voice vote and the Senate passed it by unanimous consent on 12/15/14. The President signed it into law (P.L. 113-265) on 12/18/2014.
- Read the full bill text on Congress.gov
Sunscreen Innovation Act, P.L. 113-195 (H.R. 4250/S. 2141, 113th Congress)
- The bills aim to accelerate FDA review and approval of sunscreens with new active ingredients. FDA’s Center for Drug Evaluation and Research would be required to complete its review of eligible applications within 300 days of the request being filed. If the center did not act within that time, the request would be transferred to the FDA Commissioner for review within 60 days.
- Provisions in the bills are specific to FDA, and NCI would not have any responsibility for implementation.
- H.R. 4250 was originally introduced by Rep. Ed Whitfield (R-KY) on 3/13/14, and Jack Reed (D-RI) and Johnny Isakson (R-GA) introduced a companion bill, S. 2141 on the same date. The Senate passed S. 2141 on 9/17/14, agreeing to the measure by Unanimous Consent. The House passed S. 2141 by unanimous consent on 11/13/14. The President signed it into law (P.L. 113-195) on 11/26/2014.
- Read the full bill text on Congress.gov
Gabriella Miller Kids First Research Act, P.L. 113-94 (H.R.2019, 113thCongress)
- This law amends the Internal Revenue Code to eliminate taxpayer financing of political party conventions and to reprogram savings to provide for a 10-year pediatric research initiative administered through the National Institutes of Health Common Fund.
- The bill calls for funds for political conventions currently in accounts maintained by national committees of political parties to be transferred to a fund in the Treasury to be known as the "10-Year Pediatric Research Initiative Fund" in the amount of $12.6 million per year for fiscal years 2014-2023.
- The funds are to be made available to NIH Common Fund "in such amounts as are provided in advance in appropriation Acts."
- Effect of the law is limited to identifying a specific source of funds and authorizing an appropriation to the NIH Common Fund. By itself, the law does not actually provide any funds to NIH.
- As pointed out by Reps. Nita Lowey (D-NY) and Rosa DeLauro (D-CT) (Ranking Members of the House Appropriations Committee and Labor-HHS Appropriations Subcommittee, respectively), in order for NIH to receive such funds, Congressional Appropriators must include a specific appropriation of funds in the Labor-HHS Appropriations Act each year. If this does not happen, the funds remain in the Treasury "10-Year Pediatric Research Initiative Fund" indefinitely. Reps. Lowey and DeLauro also noted that the appropriations needed to make these funds available would be fully subject to the spending caps in place under the Budget Control Act, and to the budget resolution spending allocations to the Appropriations Committee and Labor-HHS Subcommittee. This means that an increase in appropriations to NIH by the "10-Year Pediatric Research Initiative Fund" would need to be offset by a reduction elsewhere in the Labor-HHS-Education bill.
- H.R. 2019 was introduced by Rep. Gregg Harper on 5/16/13, as the Kids First Research Act, and was renamed in honor of Gabriella Miller, a 10-year-old girl from Virginia who passed away in October 2013 due to a pediatric brain tumor, Diffuse Intrinsic Pontine Glioma.
- H.R. 2019 was referred to the House Energy and Commerce Committee, Subcommittee on Health, as well as the House Committees on Administration, and Ways and Means. The bill did not proceed through mark up and was not passed out of committee. On 12/11/13, the House passed the bill under suspension of the rules, in a vote of 295-103. On 3/11/13, the Senate passed the bill by unanimous consent. The President signed the bill into law on 4/4/14.
- Read the full bill text on Congress.gov
- Learn about the implementation of the Gabriella Miller Kids First research Act and the NIH Common Fund’s Gabriella Miller Kids First Research Program
Recalcitrant Cancer Research Act of 2012, P.L. 112-239 (S. Amdt. 3180 to S. 3254/H.R. 4310, 112th Congress)
- The Act defines "recalcitrant cancers" as cancer with 5-year survival of 50%. The Act requires NCI to develop a scientific framework to conduct and support research for at least two "recalcitrant cancers," that also have a five-year survival rate of less than 20% and estimated to cause at least 30,000 deaths per year in the United States. Pancreatic cancer and a grouping of four types of lung cancer would qualify under this subset definition.
- For each recalcitrant cancer with 5-year survival of less than 20% and causes at least 30,000 deaths per year, NCI is directed to convene a working group of Federal and non-Federal entities to provide expertise and assistance in developing the scientific framework. The frameworks are to be completed within 18 months of enactment, then submitted to Congress and made publicly available on the HHS website within 30 days. The Act calls for review and update to these frameworks not later than five years after initial development, and one-time reports on the effectiveness of each framework not later than six years after initial development.
- The Act requires that actions undertaken to carry out each scientific framework be reported in the NIH Biennial report, with an assessment of progress made in improving outcomes for recalcitrant cancers.
- The Act further states that the NCI Director "shall consider each relevant scientific framework when making recommendations for exception funding for grant applications."
The NCI is meeting the requirements of the RCRA and has already delivered to Congress “scientific framework” reports on both pancreatic ductal adenocarcinoma (PDAC) and small cell lung cancer (SCLC), two cancer types meeting the criteria for cancers as defined in the RCRA. Reports to NCI’s Clinical and Translational Research Advisory Committee (CTAC) at regular intervals will inform the public of progress on PDAC and SCLC (read the November 2015 update and report; read the March 2015 update; read the November 2014 update). This approach, it should be noted, is not unique to these cancer types: workshops to identify scientific opportunities relevant to many types of cancer occur as part of NCI's standard practices.
The scientific framework for PDAC was completed and delivered to Congress in February 2014. NCI is addressing the recommendations made in that report, including the relationship between PDAC and diabetes mellitus of recent onset; biomarker and imaging studies of pancreatic cysts to identify those at high risk of PDAC; and new immunotherapies. NCI has also begun the RAS Initiative to develop new ways to treat cancers, including PDAC, that are commonly driven by mutations in the RAS gene family. One of the three RAS genes is often mutated in pancreatic, lung, and colorectal cancers, as well as several other cancer types, yet methods for treating such tumors have been difficult to produce. NCI is also investing in the training of the next generation of RAS experts and has joined with the Pancreatic Cancer Action Network to support two training fellowships focused on a type of RAS mutation relevant to pancreatic cancer.
The scientific framework for small cell lung cancer (SCLC) was completed and delivered to Congress in June 2014. The NCI is currently pursuing several research efforts in support of the initiatives recommended in the framework. These include optimizing the collection of tumor tissue specimens representing distinct phases of SCLC (from initial diagnosis to disease recurrence following radio-chemotherapy); developing new tumor models (conditionally-reprogrammed cell lines, patient-derived xenografts, and genetically-engineered mouse models) that reflect the phases of SCLC found in the clinic; expanding comprehensive genomic profiling studies of SCLC specimens; investigating new diagnostic approaches for populations at high risk of developing SCLC; focusing therapeutic development efforts on specific molecular vulnerabilities of SCLC; and investigating the mechanisms underlying both the high initial rate of response to primary SCLC therapy and the rapid emergence of drug and radiation resistance following completion of treatment.